Cargando…

Clinical characteristics of non-small cell lung cancer harboring mutations in exon 20 of EGFR or HER2

Unlike common epidermal growth factor receptor gene (EGFR) mutations that confer sensitivity to tyrosine kinase inhibitors (TKIs) in non-small cell lung cancer (NSCLC), mutations in exon 20 of either EGFR or the human EGFR2 gene (HER2) are associated with insensitivity to EGFR-TKIs, with treatment o...

Descripción completa

Detalles Bibliográficos
Autores principales:	Takeda, Masayuki, Sakai, Kazuko, Hayashi, Hidetoshi, Tanaka, Kaoru, Tanizaki, Junko, Takahama, Takayuki, Haratani, Koji, Nishio, Kazuto, Nakagawa, Kazuhiko
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2018
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5940408/ https://www.ncbi.nlm.nih.gov/pubmed/29765525 http://dx.doi.org/10.18632/oncotarget.24958

Ejemplares similares

Durable response to EGFR tyrosine kinase inhibitors in a patient with non–small cell lung cancer harboring an EGFR kinase domain duplication
por: Hirokawa, Esuteru, et al.
Publicado: (2021)

A case of ALK-rearranged non–small cell lung cancer that responded to ceritinib after development of resistance to alectinib
por: Makuuchi, Yosuke, et al.
Publicado: (2018)

Heregulin expression and its clinical implication for patients with EGFR-mutant non-small cell lung cancer treated with EGFR-tyrosine kinase inhibitors
por: Yonesaka, Kimio, et al.
Publicado: (2019)

Aberrant HER3 ligand heregulin-expressing head and neck squamous cell carcinoma is resistant to anti-EGFR antibody cetuximab, but not second-generation EGFR-TKI
por: Yonesaka, Kimio, et al.
Publicado: (2019)

Targeting of the HER2/HER3 signaling axis overcomes ligand‐mediated resistance to trastuzumab in HER2‐positive breast cancer
por: Watanabe, Satomi, et al.
Publicado: (2019)

Nintedanib promotes antitumour immunity and shows antitumour activity in combination with PD-1 blockade in mice: potential role of cancer-associated fibroblasts
por: Kato, Ryoji, et al.
Publicado: (2020)

Heregulin-expressing HER2-positive breast and gastric cancer exhibited heterogeneous susceptibility to the anti-HER2 agents lapatinib, trastuzumab and T-DM1
por: Nonagase, Yoshikane, et al.
Publicado: (2016)

Clinical and immune profiling for cancer of unknown primary site
por: Haratani, Koji, et al.
Publicado: (2019)

New Era for Next-Generation Sequencing in Japan
por: Takeda, Masayuki, et al.
Publicado: (2019)

The pan-HER family tyrosine kinase inhibitor afatinib overcomes HER3 ligand heregulin-mediated resistance to EGFR inhibitors in non-small cell lung cancer
por: Yonesaka, Kimio, et al.
Publicado: (2015)

Mutational activation of the epidermal growth factor receptor down‐regulates major histocompatibility complex class I expression via the extracellular signal‐regulated kinase in non–small cell lung cancer
por: Watanabe, Satomi, et al.
Publicado: (2018)

Novel single nucleotide polymorphism biomarkers to predict opioid effects for cancer pain
por: Fujita, Yoshihiko, et al.
Publicado: (2023)

A Randomized Phase II Study Comparing Nivolumab with Carboplatin–Pemetrexed for EGFR-Mutated NSCLC with Resistance to EGFR Tyrosine Kinase Inhibitors (WJOG8515L)
por: Hayashi, Hidetoshi, et al.
Publicado: (2022)

The Tumor Immune Microenvironment and Frameshift Neoantigen Load Determine Response to PD-L1 Blockade in Extensive-Stage SCLC
por: Kanemura, Hiroaki, et al.
Publicado: (2022)

Peritumoural ground-glass opacity associated with tumour pseudoprogression in a patient with non-small cell lung cancer treated with nivolumab
por: Kato, Ryoji, et al.
Publicado: (2017)

Successful long-term treatment of non–small cell lung cancer positive for RET rearrangement with pemetrexed
por: Takeda, Masayuki, et al.
Publicado: (2019)

Tumor tissue and plasma levels of AXL and GAS6 before and after tyrosine kinase inhibitor treatment in EGFR‐mutated non–small cell lung cancer
por: Nonagase, Yoshikane, et al.
Publicado: (2019)

Predicting osimertinib‐treatment outcomes through EGFR mutant‐fraction monitoring in the circulating tumor DNA of EGFR T790M‐positive patients with non‐small cell lung cancer (WJOG8815L)
por: Sakai, Kazuko, et al.
Publicado: (2020)

Multiple regulatory mechanisms of hepatocyte growth factor expression in malignant cells with a short poly(dA) sequence in the HGF gene promoter
por: SAKAI, KAZUKO, et al.
Publicado: (2015)

A case of severe cerebral embolism after chemotherapy for HER2-positive gastric cancer
por: Takahama, Takayuki, et al.
Publicado: (2015)

Clinical Application of the FoundationOne CDx Assay to Therapeutic Decision‐Making for Patients with Advanced Solid Tumors
por: Takeda, Masayuki, et al.
Publicado: (2021)

Association of EGFR Exon 19 Deletion and EGFR-TKI Treatment Duration with Frequency of T790M Mutation in EGFR-Mutant Lung Cancer Patients
por: Matsuo, Norikazu, et al.
Publicado: (2016)

HER2 genomic amplification in circulating tumor DNA and estrogen receptor positivity predict primary resistance to trastuzumab emtansine (T-DM1) in patients with HER2-positive metastatic breast cancer
por: Sakai, Hitomi, et al.
Publicado: (2018)

Efficacy of Crizotinib After Entrectinib Resistance Due to MET Polysomy in ROS1-Rearranged NSCLC: A Case Report
por: Takakura, Toshiaki, et al.
Publicado: (2023)

A comparative study of curated contents by knowledge-based curation system in cancer clinical sequencing
por: Sakai, Kazuko, et al.
Publicado: (2019)

Association of immune-related adverse events with immune checkpoint inhibitor efficacy: real or imaginary?
por: Haratani, Koji, et al.
Publicado: (2020)

Intestinal Microbiota and Gene Expression Reveal Similarity and Dissimilarity Between Immune-Mediated Colitis and Ulcerative Colitis
por: Sakai, Kazuko, et al.
Publicado: (2021)

Differential roles of trans-phosphorylated EGFR, HER2, HER3, and RET as heterodimerisation partners of MET in lung cancer with MET amplification
por: Tanizaki, J, et al.
Publicado: (2011)

Successful osimertinib treatment for leptomeningeal carcinomatosis from lung adenocarcinoma with the T790M mutation of EGFR
por: Sakai, Hitomi, et al.
Publicado: (2017)

Treatment of EGFR mutation–positive non–small cell lung cancer complicated by Trousseau syndrome with gefitinib followed by osimertinib: a case report
por: Nonagase, Yoshikane, et al.
Publicado: (2018)

Morphine Versus Oxycodone for Cancer Pain Using a Catechol-O-methyltransferase Genotype Biomarker: A Multicenter, Randomized, Open-Label, Phase III Clinical Trial (RELIEF Study)
por: Matsuoka, Hiromichi, et al.
Publicado: (2022)

Gene amplification of EGFR, HER2, FGFR2 and MET in esophageal squamous cell carcinoma
por: KATO, HIROAKI, et al.
Publicado: (2013)

Clinical implications of bronchoscopy for immune checkpoint inhibitor-related pneumonitis in patients with non-small cell lung cancer
por: Nishiyama, Osamu, et al.
Publicado: (2021)

Targeting MET Amplification as a New Oncogenic Driver
por: Kawakami, Hisato, et al.
Publicado: (2014)

Detection of the T790M mutation of EGFR in plasma of advanced non–small cell lung cancer patients with acquired resistance to tyrosine kinase inhibitors (West Japan oncology group 8014LTR study)
por: Takahama, Takayuki, et al.
Publicado: (2016)

Interstitial lung disease associated with capmatinib therapy in a patient with non‐small cell lung cancer harboring a skipping mutation of MET exon 14
por: Kanemura, Hiroaki, et al.
Publicado: (2020)

HER2 genomic amplification in circulating tumor DNA from patients with cetuximab-resistant colorectal cancer
por: Takegawa, Naoki, et al.
Publicado: (2015)

Lack of Association of Plasma Levels of Soluble Programmed Cell Death Protein 1, Programmed Death-Ligand 1, and CTLA-4 With Survival for Stage II to IIIA NSCLC After Complete Resection and Adjuvant Chemotherapy
por: Tanizaki, Junko, et al.
Publicado: (2023)

FGFR gene alterations in lung squamous cell carcinoma are potential targets for the multikinase inhibitor nintedanib
por: Hibi, Masaaki, et al.
Publicado: (2016)

Impact of ramucirumab plus erlotinib on circulating cell-free DNA from patients with untreated metastatic non-small cell lung cancer with EGFR-activating mutations (RELAY phase 3 randomized study)
por: Nishio, Kazuto, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_57boh33ghl0juc6aphf3ckss6q